Stereotactic Radiotherapy for Sinonasal Malignancy (NCT06617910) | Clinical Trial Compass
Active — Not RecruitingNot Applicable
Stereotactic Radiotherapy for Sinonasal Malignancy
Taiwan16 participantsStarted 2023-09-01
Plain-language summary
Sinonasal Tumors are a rare type of head and neck tumor, accounting for approximately 3% of head and neck cancers. Treatment primarily involves surgical intervention, with radiation therapy as an adjunct. Due to the tumor\'s anatomical location near critical structures such as the eyes, optic nerves, optic chiasm, brainstem, and oral cavity, if the tumor cannot be completely resected, postoperative radiation therapy is often necessary. Given the complexity of the tumor\'s anatomical position, subsequent radiation therapy planning becomes more challenging, as it must balance tumor control and organ preservation. This study retrospectively analyzes patients with sinonasal tumors who received stereotactic radiosurgery (CyberKnife) at our hospital, comparing the dosimetric advantages, treatment efficacy, survival analysis, and side effects with those of volumetric modulated arc therapy (VMAT).
Who can participate
Age range
20 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* The pathological tissue report from the endoscopic surgery at this hospital confirmed a diagnosis of malignant sinus tumor.
* Received radical stereotactic radiotherapy at this hospital.
* Pre-treatment baseline imaging (CT or MRI) was performed.
* Received radical radiotherapy at this hospital and has been under long-term follow-up with complete medical records at this hospital.
Exclusion Criteria:
* Local lymphatic metastasis and distant metastasis have been excluded by imaging examinations (cN \>=1, M =1).
* Not treated with radical radiotherapy at this hospital and has been under long-term follow-up at this hospital with incomplete medical records.
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Overall Survival, OS
Timeframe: Data within five years after treatment.
2
Disease-Free Survival, DFS
Timeframe: Data within five years after treatment
3
Local Control, LC
Timeframe: The observation periods are 1 year, 3 years, and 5 years after treatment.
4
Distant Metastasis-Free Survival, DMFS
Timeframe: The observation periods are 1 year, 3 years,and 5 years after treatment.